{"data":[{"accessionNo":"0000919574-26-006906","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"G8128Y157","securityClass":"Ordinary Shares, nominal value 0.05 GBP per share","eventDate":"2026-10-05","reportingPerson":"Reade E. Griffith","reportingCik":null,"personType":"IN","sharesOwned":9878565,"percentOfClass":5.3,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0000919574-26-006906","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"G8128Y157","securityClass":"Ordinary Shares, nominal value 0.05 GBP per share","eventDate":"2026-10-05","reportingPerson":"Tetragon Financial Management LP","reportingCik":null,"personType":"IA,PN","sharesOwned":9878565,"percentOfClass":5.3,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0000919574-26-006906","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"G8128Y157","securityClass":"Ordinary Shares, nominal value 0.05 GBP per share","eventDate":"2026-10-05","reportingPerson":"Tetragon Financial Group Limited","reportingCik":null,"personType":"OO","sharesOwned":9878565,"percentOfClass":5.3,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0000919574-26-006906","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"G8128Y157","securityClass":"Ordinary Shares, nominal value 0.05 GBP per share","eventDate":"2026-10-05","reportingPerson":"Patrick G. G. Dear","reportingCik":null,"personType":"IN","sharesOwned":9878565,"percentOfClass":5.3,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0000919574-26-006888","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"G8128Y157","securityClass":"Ordinary Shares, nominal value 0.05 GBP per share","eventDate":"2026-10-05","reportingPerson":"Reade E. Griffith","reportingCik":null,"personType":"IN","sharesOwned":9708153,"percentOfClass":5.2,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0000919574-26-006888","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"G8128Y157","securityClass":"Ordinary Shares, nominal value 0.05 GBP per share","eventDate":"2026-10-05","reportingPerson":"Patrick G. G. Dear","reportingCik":null,"personType":"IN","sharesOwned":9708153,"percentOfClass":5.2,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0000919574-26-006888","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"G8128Y157","securityClass":"Ordinary Shares, nominal value 0.05 GBP per share","eventDate":"2026-10-05","reportingPerson":"Tetragon Financial Management LP","reportingCik":null,"personType":"IA,PN","sharesOwned":9708153,"percentOfClass":5.2,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0000919574-26-006888","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"G8128Y157","securityClass":"Ordinary Shares, nominal value 0.05 GBP per share","eventDate":"2026-10-05","reportingPerson":"Tetragon Financial Group Limited","reportingCik":null,"personType":"OO","sharesOwned":9708153,"percentOfClass":5.2,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0001104659-26-096202","formType":"SCHEDULE 13D/A","amendmentNo":11,"issuerCik":"0001479615","issuerName":"Silence Therapeutics Plc","ticker":"SLN","cusip":"G8128Y157","securityClass":"Ordinary Shares, nominal value of PS0.05 per share","eventDate":"2026-08-12","reportingPerson":"Richard Griffiths","reportingCik":"0001846370","personType":"IN","sharesOwned":14391498,"percentOfClass":7.97,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0002005369-26-000047","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"82686Q101","securityClass":"Ordinary share, nominal value 0.05 GBP per share","eventDate":"2026-06-30","reportingPerson":"Raymond Debbane","reportingCik":null,"personType":"IN","sharesOwned":9934314,"percentOfClass":7,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0002005369-26-000047","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"82686Q101","securityClass":"Ordinary share, nominal value 0.05 GBP per share","eventDate":"2026-06-30","reportingPerson":"Invus Public Equities Advisors, LLC","reportingCik":null,"personType":"OO","sharesOwned":8707287,"percentOfClass":6.1,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0002005369-26-000047","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"82686Q101","securityClass":"Ordinary share, nominal value 0.05 GBP per share","eventDate":"2026-06-30","reportingPerson":"Invus Public Equities, L.P.","reportingCik":null,"personType":"PN","sharesOwned":8707287,"percentOfClass":6.1,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0002005369-26-000047","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"82686Q101","securityClass":"Ordinary share, nominal value 0.05 GBP per share","eventDate":"2026-06-30","reportingPerson":"Invus Global Management, LLC","reportingCik":null,"personType":"OO","sharesOwned":8707287,"percentOfClass":6.1,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0002005369-26-000047","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"82686Q101","securityClass":"Ordinary share, nominal value 0.05 GBP per share","eventDate":"2026-06-30","reportingPerson":"Siren, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":8707287,"percentOfClass":6.1,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0002005369-26-000047","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"82686Q101","securityClass":"Ordinary share, nominal value 0.05 GBP per share","eventDate":"2026-06-30","reportingPerson":"Avicenna Life Sci Master GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1227027,"percentOfClass":0.9,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0002005369-26-000047","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"82686Q101","securityClass":"Ordinary share, nominal value 0.05 GBP per share","eventDate":"2026-06-30","reportingPerson":"Ulys, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":1227027,"percentOfClass":0.9,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0002005369-26-000047","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":"82686Q101","securityClass":"Ordinary share, nominal value 0.05 GBP per share","eventDate":"2026-06-30","reportingPerson":"Avicenna Life Sci Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":1227027,"percentOfClass":0.9,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0001104659-26-081559","formType":"SCHEDULE 13D/A","amendmentNo":10,"issuerCik":"0001479615","issuerName":"Silence Therapeutics Plc","ticker":"SLN","cusip":"G8128Y157","securityClass":"Ordinary Shares, nominal value of PS0.05 per share","eventDate":"2026-07-06","reportingPerson":"Richard Griffiths","reportingCik":"0001846370","personType":"IN","sharesOwned":30844458,"percentOfClass":21.7,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0001104659-26-081559","formType":"SCHEDULE 13D/A","amendmentNo":10,"issuerCik":"0001479615","issuerName":"Silence Therapeutics Plc","ticker":"SLN","cusip":"G8128Y157","securityClass":"Ordinary Shares, nominal value of PS0.05 per share","eventDate":"2026-07-06","reportingPerson":"Ora Capital Limited","reportingCik":null,"personType":"CO","sharesOwned":19155522,"percentOfClass":13.5,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/sln"},{"accessionNo":"0000908834-26-000072","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001479615","issuerName":"Silence Therapeutics plc","ticker":"SLN","cusip":null,"securityClass":"Ordinary Shares, par value GBP 0.05 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Lombard Odier Asset Management (USA) Corp","reportingCik":null,"personType":"IA,OO","sharesOwned":5935955,"percentOfClass":4.2,"filedAt":"2026-02-09","canonicalUrl":"https://xoomar.com/markets/stocks/sln"}],"updatedAt":"2026-11-04T04:20:49.886Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/sln","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}